top button
    Got Questions


Global IoT Summit 2018
Oct 31, 2018
The Leela Palace, Bangalore



    Connect to us
      Facebook Login
      Site Registration Why to Join

Facebook Login
Site Registration

Monoclonal Antibody Therapeutics Market Companies Detailed in New Research Report

0 votes
4 views

In the global monoclonal antibody therapeutics market, keen companies are seen partnering with both their local and international counterparts to take advantage of synergies. It enables them to reduce the cost of production, funnel greater amounts into research and development, and gain access to better human resources. Pfizer Inc., Novartis AG, Bayer AG, Sanofi, F. Merck & Co., Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., and AbbVie Inc. are to name a few prominent participants in the global market for monoclonal antibody therapeutics

A recent research study by Transparency Market Research projects the market for monoclonal antibody therapeutics to attain a value of US$245.8 bn by the end of the forecast period in 2024 by rising at a solid double digit 12.6% CAGR from 2016 to 2024. The estimated valuation of the market as per our report was US$86.7 bn at the start of the forecast period in 2015.

Request PDF Sample of Monoclonal Antibody Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=18209

Monoclonal antibody therapeutics mostly find application in treating autoimmune diseases. This is because of the rising awareness about such diseases and their treatments, better accessibility to healthcare, and the growing applications of monoclonal antibody therapeutics on account of major thrust on their research and development. Going forward too, the rising cases of autoimmune diseases expected to generate maximum opportunities in the market. From a geographical standpoint, Europe and North America together accounted for a share of 62.7% in the global market for monoclonal antibodies therapeutics in 2015. Their market has been stoked by the rising number of elderly, solid reimbursement policies and affordable healthcare, and a strong knowledge about various diseases.

Surging Cancer Cases Underpin Demand in Market

Monoclonal antibody therapeutics is essentially a biological therapy that finds usage in treating different kinds of chronic conditions. Rheumatoid arthritis, cancer, Crohn’s diseases, osteoporosis, systemic lupus erythematous, and psoriasis, among others, can be treated leveraging the therapeutics. Monoclonal antibodies target just the affected areas to annihilate the diseased cells, thus helping the immune system to rebound. The surging cancer cases worldwide is a major driver of the monoclonal antibody therapeutics market. As per the WHO, cancer cases are expected to rise by 70.0% in the next couple of years and this will spell immense opportunities for the market.

Buy Now “Monoclonal Antibody Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=18209&ltype=S

Apart from rising cases of cancer, investments into research and development of new antibodies, especially in the U.S. and Europe, along with speedy approval and commercialization of these drugs will also contribute to the surging revenue in the market. Our report finds that around five to six monoclonal antibodies receive a nod from regulatory bodies in these regions every year for launch in market.

Biosimilars, Used in Treating Similar Medical Conditions, Slow Down Demand for Monoclonal Antibodies

Despite the bright potential of the market, it is expected to be hobbled by the growing manufacture of biosimilars, which also find application in treating different autoimmune diseases and chronic conditions. In addition, expiry of patents for many monoclonal antibodies coupled with expensive and complex manufacturing process is hampering market growth. All such factors are serving to drive up prices of the final product thereby dampening sales.

More Trending Reports by Transparency Market Research –

Single-Cell Analysis Market: globenewswire.com/news-release/2019/05/20/1828056/0/en/Single-Cell-Analysis-Market-to-rise-at-a-healthy-15-4-CAGR-till-2025-Consumables-Segment-Held-Dominant-Share-TMR.html

Antimicrobial Susceptibility Test Market: globenewswire.com/news-release/2019/07/18/1884570/0/en/Antimicrobial-Susceptibility-Test-Market-to-generate-US-3-814-0-million-revenue-by-2025-Noted-TMR.html

posted 4 days ago by Bella Watson

  Promote This Article
Facebook Share Button Twitter Share Button Google+ Share Button LinkedIn Share Button Multiple Social Share Button

Related Articles
0 votes

Transparency Market Research (TMR) has published a new report titled “Drug Delivery System Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. According to the, the global drug delivery system market was valued at approximately US$ 510.0 Bn in 2016 is projected to expand at CAGR of over 6.9% from 2017 to 2025. The report suggests that rise in prevalence of diseases and increases in demand for self-administration devices are likely to spur demand for drug delivery system in the during the forecast period (2017 to 2025).

Key players introduce new drugs delivery systems and devices in developed markets such a North America and Western Europe. Hence, these regions are likely to account for dominant share of the global drug delivery system market. Rise in R&D investment and launch of new and advanced technologies in emerging markets such as Japan and India are expected to boost the drug delivery system market in Asia Pacific. The market in the region is expected to expand at a CAGR of around 7.6% from 2017 to 2025.

Targeted Drug Delivery System Dominates the Market Followed by Polymeric Drug Delivery

The report offers detailed segmentation of the global drug delivery system market based on delivery system, application, route of administration, and geography. In terms of delivery system, the targeted drug delivery segment is expected to account for a dominant share of the global market during the forecast period. Simplified drug administration protocols, avoidance of first pass metabolism, lower dose required as compared to the conventional drug delivery, and higher therapeutic effect in small doses are some factors propelling the segment.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=41543

The polymeric drug delivery segment is likely to expand at a considerable growth rate during the forecast period. Polymeric drug delivery systems allow localized drug delivery in large quantity for the treatment of chronic diseases such as cancer (more specifically, solid tumors) with lower toxicity. This is a major factor driving the segment.

Oncology and CNS: Top Two Application Areas of the Drug Delivery System Market

Based on application, the oncology segment is projected to hold a dominant share of the global drug delivery system market during the forecast period. It is likely to expand at CAGR of more than 7.4% from 2017 to 2025. Dominance of this segment is attributed to continuous innovations in drug offerings and wide product portfolio of major and local manufacturers. For instance, in September, 2017, Amgen Inc. and ALLERGAN collectively obtained FDA approval for the use of MVASI to treat five types of cancer, which includes metastatic carcinoma of the cervix, metastatic renal cell carcinoma, glioblastoma, metastatic colorectal cancer (mCRC), and non-squamous non-small cell lung cancer (NSCLC).

Continuous launch of new products and increase in the number of patients in developed and developing countries are likely to drive the segment between 2017 and 2025. According to WHO report, in 2015, around 8.8 million people died of cancer, of which, around 1.69 million died of lung cancer and 788,000 succumbed to liver cancer. This highlights the significant need for advanced drug delivery system to treat cancer. CAN and diabetes segment, accounted for more than 36.0% share of global drug delivery system market in 2016, in terms of value. It is anticipated to have substantial growth and account for approximately 36% of market share by 2025.

Buy Now Drug Delivery Systems Market Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=41543&ltype=S

Asia Pacific to Expand at an Exponential Growth Rate and Offer Significant Incremental Opportunity

In terms of value, North America was leading contributor to the global drug delivery system market in 2016. North America accounted for a key share of the market due to rise in prevalence of acute and chronic diseases in the U.S. According to WHO report 2016, non-communicable diseases accounted for 23% of total deaths in the U.S. Moreover, availability of advanced technology and facilities in the health care system also drive the drug delivery system market in the U.S.

Moreover, rise in research & development spending in emerging markets such as Singapore and Japan is fueling the market in Asia Pacific. Economic growth in countries such as Brazil is increasing health care expenditure through the rise in private health insurance and entry of international drug manufacturers and health care providers in Latin America. Hence, the market in the region is likely to expand at a CAGR of 5.5% from 2017 to 2025.

Key Players such as Boston Scientific Corporation, Johnson & Johnson Services, Inc. and Pfizer, Inc. are Likely to Continue to Lead the Global Drug Delivery System Market

The report also provides profiles of leading players operating in the global drug delivery system market, which include AstraZeneca plc., Pfizer Inc., Novartis AG, Bayer AG, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Amgen Inc., Becton, Dickinson and Company, and Baxter International Inc. These player engage in expansion of drugs delivery system portfolio by improving existing drug delivery devices and developing and launching of new drug delivery system through collaboration. For instance, Becton, Dickinson and Company developed and launched 6mm pen needle for insulin to treat diabetes.

0 votes

The wound healing market is expected to witness robust growth in the near future, as rising number of accidents, and increasing access to healthcare fuels growth. The market will likely rise to US$35,065.7 mn in evaluation by the end of 2025, rising at 4.80% CAGR. Advanced wound care is likely to drive robust growth in developed countries, due to major increases in chronic illnesses, and advanced technology.

Among applications, the hemostatic agents are likely to witness robust growth as cases of accidents, chronic illnesses, and advancements in products drive growth. Rising number of diabetics will also promise new opportunities for players in the wound healing market.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=40535

Among regions, Asia Pacific will drive robust growth for the wound healing market. The region is home to large number of accidents, and currently witnessing an expansion of privatised insurance scheme which will drive robust demand for the wound healing market in the near future. the rising access to healthcare in the region will also promise new opportunities for players in the wound healing market in the near future.

Diabetics to Fuel Growth for the Wound Healing Market

Population of diabetics is increasing around the world. Rising urbanization, and unhealthy foods, and genetic factors are expected to increase these numbers based on empirical evidence from previous years. The rising numbers of diabetics will likely result in specialised, and sensitive methodology to treat wounds, and heal them effectively. The rise of chronic illnesses like most forms of cancers will also drive major growth for the wound healing market in the near future.

Buy Now @ https://www.transparencymarketresearch.com/checkout.php?rep_id=40535&ltype=S

The innovations, and developments in this area including Big Data, which helps understand causation between illnesses and genetic factors, as well as combinations for drug manufacturing will create new opportunities for players in the wound healing market in the near future. The risk associated with wound care cosmetics, and high costs of some of these products are expected to remain a major barrier to growth in the wound healing market. Facial makeover treatment remain expensive as several patients of accidents continue to suffer to restrain prospects of the wound healing market.

0 votes

The global rheumatology therapeutics market is highly competitive and consolidated due to presence of strong players, finds Transparency Market Research (TMR). Some of the key players operating in the global rheumatology therapeutics market are AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., Merck & Co., Inc., Amgen, Inc., Novartis AG, Janssen Biotech, Inc., Sanofi, Genentech, Inc., and Takeda Pharmaceutical. Among them, the companies such as AbbVie, Inc., Bristol-Myers Squibb Company, Pfizer, Inc., and Merck & Co., Inc. are accounts for the leading share in the global rheumatology therapeutics market.

TMR anticipated the global revenue of the rheumatology therapeutics market was registered in 2016 US$41.88 bn and expected to expand with a CAGR of 2.7% over the forecast period from 2017 to 2025 and expected to attain value of a US$ 52.96 bn by the end of 2025. On the basis of drug class, the segment biologic DMARDs has registered at the revenue of US$35.83 bn in 2016 is expected to rise at a 2.6% CAGR with this growth rate in a revenue of US$45.06 bn by 2025. This growth is attributable to high usage of Azathioprine, cyclosporine, cyclophosphamide, and methotrexate. On the basis of region, North America accounts for a leading share in the global rheumatology therapeutics market owing to rapid rise in the elderly population.

Request PDF Sample of Rheumatology Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494

Rising Prevalence of Rheumatology Diseases to Boost Growth

Rheumatology diseases generally effects on the supporting and connecting structures and bones of the body such as joints, muscles, ligaments, tendons and some of the organs of body. It is characterized by effects on spine and inflammation of joints occurred in some of the symptoms of rheumatology disease. Early diagnosis and treatment on symptoms of rheumatology disease. Physicians generally prescribe disease-modifying anti-rheumatic drugs (DMARD’s) for treatment of rheumatologic disease. Rising prevalence of rheumatology diseases are boosting requirement of its treatments which is fuelling growth of the global rheumatology therapeutics market.

Additionally, technological advancements in pharmaceutical field coupled with increasing investments in healthcare industry for research and development activities. Rising trend for fitness globally which is expected to support the growth of rheumatology therapeutics market. Increasing expenditure on healthcare from mid-earing population is driving growth of the global rheumatology therapeutics market.

Buy Now “Rheumatology Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=1494&ltype=S

Availability of Alternatives for Rheumatology Therapeutics to Hamper Growth

However, launch of biosimilars is key factors hampering growth of the rheumatology therapeutics market. Rising demand for biosimilar products are crimping growth of the rheumatology therapeutics market. Additionally, patent expiry of well-known drugs used in the treatment of rheumatology diseases is hampering growth of the rheumatology therapeutics market. Nevertheless, increasing launches of novel biologics drugs and rising penetration of generic drugs are expected to drive growth of the market. Increasing approvals for new biologics such as Xeljanz are anticipated to account for high penetration which is likely to create opportunities in the global rheumatology therapeutics market.

More Trending Reports by Transparency Market Research –

Tissue Engineered Skin Substitutes Market: globenewswire.com/news-release/2019/01/23/1704315/0/en/Tissue-Engineered-Skin-Substitutes-Market-to-reach-around-US-3-87-billion-by-2023-TMR.html

Collagen Market: globenewswire.com/news-release/2019/05/15/1825247/0/en/Collagen-Market-to-Expand-at-a-CAGR-of-9-4-by-2023-Marine-Collagen-to-Gain-Maximum-Prominence-Says-TMR.html

0 votes

Transparency Market Research (TMR) has published a new report titled, “Adult Malignant Glioma Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global adult malignant glioma therapeutics market was valued at US$ 1,349.6 Mn in 2017 and is projected to expand at a CAGR of 9.2% from 2018 to 2026. The global market is anticipated to witness steady growth owing to promising effective therapies in the pipeline for addressing the gaps in treatment.

Development of a promising drug to treat malignant glioma has proved difficult to date, with a number of promising candidates failing to achieve the desired test results in the past few years. However, technological advancements in the diagnosis of gliomas and analysis of its progression through various imaging modalities has improved the survival rates, thereby giving an enhanced edge for rapid evaluation of efficacy of several pipeline drugs. North America and Europe are projected to dominate the global adult malignant glioma therapeutics market during the forecast period, primarily due to the significant reimbursement coverage. The market in Asia Pacific is expected to expand at a significant CAGR from 2018 to 2026.

Rise in Patient Population and Expedited Drug Discovery Process to Drive Market

According to the World Health Organization, globally, an estimated 245,000 cases of brain and nervous system tumors are reported each year. Glioblastoma multiforme is the most common and the most lethal of these tumors. Gliomas are categorized under rare diseases; however, the incidence rate across the globe has witnessed steady rise in the last decade. Adoption of novel drug discovery technologies, such as high-throughput screening and TCGA, has reduced the overall drug discovery time and the cost of drug development. This is attributed to rise in the number of players participating in new product development and launches in various therapy areas, including glioma. These factors are likely to drive the global adult malignant glioma therapeutics market during the forecast period.

Request PDF Sample of Adult Malignant Glioma Therapeutics Market Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=13211

Glioblastoma Multiforme Segment to Continue to Dominate Market

In terms of type, the global adult malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. The glioblastoma multiforme segment is projected to hold dominant share of the global market during the forecast period, owing to gradual rise in adoption of novel drug therapies, rapidly increasing patient population, surge in investment in research and development of targeted therapies to improve survival rates, and significant improvements in hospital infrastructure in high growth potential developing countries.

Targeted Drug Therapy to be Major Segment with Above-average Growth Rate

In terms of therapy, the global adult malignant glioma therapeutics market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy. The chemotherapy segment has been classified into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been categorized into EGFR inhibitors, other monoclonal antibodies, and others. The targeted drug therapy segment dominated the global adult malignant glioma therapeutics market in 2017 owing to high cost of therapy and high patient preference. The segment is also likely to register above-average growth rate due to development of new combination therapies with novel technologies such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others, and rise in focus on reducing cost of care to address the demand for affordable care.

High Adoption of Advanced Therapeutics in Developed Markets

North America and Europe held over 60% share of the global adult malignant glioma therapeutics market in 2017. This is attributed to higher cost of therapy than that in developing regions, high adoption rate of technologically-advanced products, greater reimbursement coverage that ensures return on investment for emerging market entrants, and provision of orphan drug designation that aids in the process of drug approval. Developing countries such as China and India are likely to offer significant opportunities during the forecast period owing to above average incidence rate of malignant gliomas, significant geriatric population, rise in awareness about early diagnosis and treatment compliance, and improving health care infrastructure. The market in these countries is highly price sensitive and regulated by a government cap on the prices of therapeutics.

Buy Now “Adult Malignant Glioma Therapeutics Market ” Research Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=13211&ltype=S

Highly Consolidated Market with Low to Moderate Risk of New Entrants

The global adult malignant glioma therapeutics market is highly consolidated, with top three players accounting for more than 65% share in terms of revenue in 2017. These companies are projected to dominate the global market during the forecast period. However, the market is also likely to witness some novel drug launches with innovative mechanism of action by emerging players during the early forecast period. The report profiles leading players operating in the global adult malignant glioma therapeutics market such as F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

0 votes

With a number of established players, the global blood flow measurement devices market is demonstrating a highly competitive landscape, states a new research report by Transparency Market Research (TMR). Transonic Systems Inc., Perimed AB, Moor Instruments Ltd., Medistim ASA, GF Health Products Inc., Deltex Medical, Cook Medical Inc., Compumedics Ltd., Atys Medical., and ArjoHuntleigh Inc. are some of the key vendors of blood flow measurement devices across the world. The focus of these players is predominantly on strengthening their position in the global market and for that they are increasingly involving into strategic alliances and mergers and acquisitions. The number of players in this market is also projected to surge in the near future, giving rise to the competition, states the research study.

According to the research report, the global market for blood flow measurement devices stood at US$0.27 bn in 2012. Progressing at a CAGR of 8.70% during the period from 2013 to 2019, the market’s opportunity is anticipated to reach US$0.50 bn by the end of the forecast period. Ultrasonic doppler flowmeters, laser doppler flowmeters, and electromagnetic flowmeters are the main products available in this market. Among these, the demand for ultrasonic doppler flowmeters have been relatively higher and this trend is anticipated to remain so over the next few years, notes the market study.

Get Sample with Latest Research @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1419

Increasing Awareness Regarding Health and Fitness to Ensure North America’s Dominance

In terms of the geography, North America has been leading the worldwide market for blood flow measurement devices, thanks to the high awareness level pertaining to health and fitness among consumers. Going forward, this regional market is likely to remain on the top in the years to come on account of the rising prevalence of circulatory diseases, such as peripheral vascular diseases. Among other regional markets, Europe and Asia Pacific are expected to register significant growth over the next few years due to the increasing acceptance of minimally invasive devices and the considerable rise in the disposable income, enabling consumers to spend on expensive treatments, reports the research study.

High Prevalence of Peripheral Vascular Disorders to Boost Market

The global market for blood flow measurement devices has been witnessing a significant rise in its valuation and is expected to remain observing high growth in the near future, thanks to the augmenting demand for these device, owing to the high prevalence of peripheral vascular disorders among people across the world. These devices find extensive application in the diagnosis of diabetic complications, arterial occlusions, and intracranial monitoring in stroke and brain injury. The increasing base of geriatrics population, extremely susceptible to a wide array of diseases, is also projected to support the growth of this market, considerably, states the research report.

More Trending Reports by Transparency Market Research –

Hearing Aids Market: prnewswire.com/news-releases/hearing-aids-market-increasing-prevalence-of-hearing-loss-worldwide-augments-product-demand-says-tmr-300857268.html

Diabetes Drugs Market: prnewswire.com/news-releases/diabetes-drugs-market-value-to-reach-us584-billion-by-the-end-of-2025-transparency-market-research-663610203.html

...